Last updated on November 2018

Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer

Brief description of study

Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose chemotherapy with intensified, alkylating chemotherapy with stem cell rescue.

Clinical Study Identifier: NCT02810743

Find a site near you

Start Over

Medical spectrum Twente

Enschede, Netherlands
  Connect »